ReGen reports promising first half 2006

By staff reporter

- Last updated on GMT

ReGen Therapeutics has been tightening its belt to reduce costs as
it prepares for commercialisation of its Colostrinin nutraceutical,
but first half 2006 results indicate that prospects are good and no
further share issues are planned for now.

The UK-based company reported sales of £55,000 in the six-month period ended June 30, all related to Guildford Pharmacology Unit Limited. These it said reflect "the start of a healthy upturn in business"​. The current external pipeline looking forward is said to be around £750,000.

In his communication to accompany the results, Percy Lomax, executive chairman of ReGen, said: "The interest in a biotech company at this stage of development is not mainly about the revenue figures, but in the company's development prospect."​ Indeed the year to date has been an exciting on for ReGen, with the signing of a licensing agreement with Metagenics in North America for Colostrinin neutraceutical for early stage cognitive decline, subject to completion of conditions and US regulatory approvals.

Colostrinin complex is derived from ovine and bovine colostrum (the first milk produced by a mammal after giving birth). A human nutraceutical containing Colostrinin is expected to come to market in the first half of 2007.

ReGen is also conducting research into pharmaceutical used of Colostrinin peptides and peptide mimetics for neurodegenerative diseases including Alzheimer's, Parkinson's and Multiple Sclerosis, and into potential new uses for zolpidem in relation to certain brain traumas.

In the six months to June 30, ReGen's development costs increased from £313,000 to £360,000. But the company trimmed back other expensed from £780,000 to £760,000. Lomax indicated that much of these savings came from trimming back salaries.

On Tuesday the company convened an Extraordinary General Meeting to propose resolutions that would renew shareholder authority to issue shares and/or other securities if future fundraising is required, and/or acquisitions of complementary businesses.

A spokesperson for ReGen told that the resolutions were all approved. However for the meantime at least, there is no need for more funds.

Lomax said: "I am aware that there has been considerable speculation over financing needs and I am pleased to report that we now have over £1.2m of cash in the bank taking into account our placing in July, which raised £1.1m gross.

"Therefore the directors do not currently intend to raise further funds through a share issue."

Related topics: Dairy-based ingredients

Related news

Related products

show more

Growing Up Bioactives

Growing Up Bioactives

Glanbia Nutritionals | 13-Sep-2022 | Business Advice

Parents are prioritizing their children’s health and wellness with 66% indicating they give their child nutritional supplements once a day*. Support their...

Opportunity Alert: Mobility Matters to your Consumers

Opportunity Alert: Mobility Matters to your Consumers

NZMP (Ingredients by Fonterra) | 16-Aug-2022 | Infographic

The World Health Organization says mobility is critical for healthy ageing, as it’s a core concern seniors face. With mobility’s significant impact on...

Consumers are ditching diets for intuitive eating.

Consumers are ditching diets for intuitive eating.

Fonterra | 02-Aug-2022 | Technical / White Paper

Interest in intuitive eating is reportedly gaining as much traction with consumers as the ketogenic diet. However, without similarly strict macronutrient...

Fonterra Keeps Your Ingredients Ahead of the Curve

Fonterra Keeps Your Ingredients Ahead of the Curve

Fonterra | 26-Jul-2022 | Technical / White Paper

With health and environmental concerns in mind, consumers’ commitment to purchasing organic products continues to grow. Whether your brand is starting...

Related suppliers

Follow us


View more